chemotherapy-induced anaemia
Haematology · 2007–2019
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| darbepoetin alfa Treatment of moderate to severe chemotherapy-induced anaemia (CIA) in patients receiving myelosuppressive chemotherapy for non-myeloid malignancies. | Mar 2019 | Not recommended | none received |
| darbepoetin alfa Treatment of chemotherapy-induced anaemia in patients with non-myeloid malignancies who meet specified criteria (haemoglobin <100 g/L, at risk of transfusion,… | Nov 2007 | Recommended with restriction | no section in document |
| darbepoetin alfa Treatment of chemotherapy-induced anaemia in patients with non-myeloid malignancies who have haemoglobin level less than 100 g/L, are at risk of requiring… | Nov 2007 | Recommended with restriction | no section in document |
What the PBS pays
$191M in government benefit over 2024–25, across 197,348 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| Darbepoetin alfa | $95.4M |
| darbepoetin alfa | $95.4M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.